Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific Region clinical isolates from the SENTRY Program, 1999 to 2001

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 2049-2055

  Christiansen, K J ^a   Bell, J M ^b   Turnidge, J D ^b   Jones, R N ^c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; OXACILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ASIA; BACTERIAL GENE; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; GEOGRAPHIC DISTRIBUTION; GRAM POSITIVE BACTERIUM; GYRA GENE; HONG KONG; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PRIORITY JOURNAL; SINGAPORE; STAPHYLOCOCCUS AUREUS; TAIWAN;

ANTI-INFECTIVE AGENTS; ASIA; BACTERIA; BACTERIAL INFECTIONS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; PACIFIC OCEAN; POPULATION SURVEILLANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOUTH AFRICA;

EID: 2542456662     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.2049-2055.2004     Document Type: Article

References (36)

1. Bassetti, M., L. M. Dembry, P. A. Farrel, D. A. Callan, and V. T. Andriole. 2002. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates. Antimicrob. Agents Chemother. 46:234-238.
2. Bell, J. M., J. D. Turnidge, and R. N. Jones. 2002. Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756. Int. J. Antimicrob. Agents 19:125-132.
3. Biedenbach, D. J., R. N. Jones, and M. A. Pfaller. 2001. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (2000) in Europe, Canada and the United States. Diagn. Microbiol. Infect. Dis. 39:245-250.
4. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
5. Broskey, J., K. Coleman, M. N. Gwynn, L. McCloskey, C. Traini, L. Voelker, and R. Warren. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 45(Suppl. 1):95-99.
6. Fung-Tomc, J. C., J. Clark, B. Minassian, M. Pucci, Y. H. Tsai, E. Gradelski, L. Lamb, I. Medina, E. Huczko, B. Kolek, S. Chaniewski, C. Ferraro, T. Washo, and D. P. Bonner. 2002. In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob. Agents Chemother. 46:971-976.
7. Fung-Tomc, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:3351-3356.
8. Gales, A., H. Sader, and R. N. Jones. 2001. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999). Antimicrob. Agents Chemother. 45:1463-1466.
9. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
10. Goldstein, F. W., and J. F. Acar. 1995. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 49(Suppl. 2):36-42.
11. Gordon, K. A., M. L. Beach, D. J. Biedenbach, R. N. Jones, P. R. Rhomberg, and A. H. Mutnick. 2002. Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. 43:157-162.
12. Gordon, K. A., M. A. Pfaller, and R. N. Jones. 2002. BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). J. Antimicrob. Chemother. 49:851-855.
13. Hartman-Neumann, S., K. DenBleyker, L. A. Pelosi, L. E. Lawrence, J. F. Barrett, and T. J. Dougherty. 2001. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756. Antimicrob. Agents Chemother. 45:2865-2870.
14. Ho, P. L., W. C. Yam, T. L. Que, D. N. Tsang, W. H. Seto, T. K. Ng, and W. S. Ng. 2001. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. J. Antimicrob. Chemother. 47:655-658.
15. Ho, P. L., R. W. Yung, D. N. Tsang, T. L. Que, M. Ho, W. H. Seto, T. K. Ng, W. C. Yam, and W. W. Ng. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.
16. Ince, D., X. Zhang, L. C. Silver, and D. C. Hooper. 2002. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chemother. 46:3370-3380.
17. Jones, M. E., N. M. Boenink, J. Verhoef, K. Kohrer, and F. J. Schmitz. 2000. Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment. J. Antimicrob. Chemother. 45:353-356.
18. Jones, M. E., D. F. Sahm, N. Martin, S. Scheuring, P. Heisig, C. Thornsberry, K. Kohrer, and F. J. Schmitz. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466.
19. Jorgensen, J. H., L. M. Weigel, J. M. Swenson, C. G. Whitney, M. J. Ferraro, and F. C. Tenover. 2000. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2962-2968.
20. Kirby, J. T., A. H. Mutnick, R. N. Jones, D. J. Biedenbacb, and M. A. Pfaller. 2002. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. 43:303-309.
21. Lawrence, L. E., M. Frosco, B. Ryan, S. Chaniewski, H. Yang, D. C. Hooper, and J. F. Barrett. 2002. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. Antimicrob. Agents Chemother. 46:191-195.
22. Lee, K., H. S. Lee, S. J. Jang, A. J. Park, M. H. Lee, W. K. Song, and Y. Chong. 2001. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone. J. Korean Med. Sci. 16:262-270.
23. Luh, K. T., P. R. Hsueh, L. J. Teng, H. J. Pan, Y. C. Chen, J. J. Lu, J. J. Wu, and S. W. Ho. 2000. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob. Agents Chemother. 44:3374-3380.
24. NCCLS. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 5th ed. NCCLS document M7-A5. NCCLS, Wayne, Pa.
25. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
26. Pankuch, G. A., K. Nagai, T. A. Davies, M. R. Jacobs, and P. C. Appelbaum. 2002. Antipneumococcal activity of BMS 284756 compared to those of six other agents. Antimicrob. Agents Chemother. 46:251-254.
27. Scheel, O., D. J. Lyon, V. T. Rosdahl, F. A. Adeyemi-Doro, T. K. Ling, and A. F. Cheng. 1996. In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993. J. Antimicrob. Chemother. 37:243-251.
28. Schmitz, F. J., M. Boos, S. Mayer, H. Jagusch, and A. C. Fluit. 2002. Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 49:283-287.
29. Schmitz, F. J., M. Boos, S. Mayer, K. Kohrer, S. Scheuring, and A. C. Fluit. 2002. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones. Antimicrob. Agents Chemother. 46:934-935.
30. Schmitz, F. J., B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, M. Klootwijk, J. Verhoef, A. Fluit, H. P. Heinz, K. Kohrer, and M. E. Jones. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41:481-484.
31. Schmitz, F. J., M. E. Jones, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, A. Fluit, J. Verhoef, U. Hadding, H. P. Heinz, and K. Kohrer. 1998. Characterization of grl4, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob. Agents Chemother. 42:1249-1252.
32. Schmitz, F. J., K. Kohrer, S. Scheuring, J. Verhoef, A. Fluit, H. P. Heinz, and M. E. Jones. 1999. The stability of grlA, grlB, gyrA, gyrB and norA mutations and MIC values of five fluoroquinolones in three different clonal populations of methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 5:287-290.
33. Turnidge, J. 1995. Epidemiology of quinolone resistance. Eastern hemisphere. Drugs 49(Suppl. 2):43-47.
34. Weller, T. M., J. M. Andrews, G. Jevons, and R. Wise. 2002. The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J. Antimicrob. Chemother. 49:177-184.
35. Wise, R., T. Gee, G. Marshall, and J. M. Andrews. 2002. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate. Antimicrob. Agents Chemother. 46:242-244.
36. Yamaguchi, K., A. Ohno, F. Kashitani, M. Iwata, Y. Shimizu, S. Sato, I. Matsumoto, M. Itoh, T. Funato, Y. Tsujio, M. Nagasawa, M. Tachibana, H. Kanno, K. Matsuda, J. Okada, H. Takaya, T. Nakamura, J. Igari, K. Sugimoto, T. Oguri, S. Toyoshima, M. Okada, T. Nakai, M. Kuwabara, Z. Nagasawa, et al. 1999. In vitro activities of 23 antimicrobial agents against 4,993 gram-positive and gram-negative bacterial strains isolated from multicenter of Japan during 1994-in vitro susceptibility surveillance. Levofloxacin-Surveillance Group. Jpn. J. Antibiot. 52:75-92.